8/6/2019 Scientist/Senior scientist/ Senior Scientific Investigator

1/3

EVELYNE ODETTE DELORME, PH.D(858) 558-2643(858) 354-1572

SENIOR SCIENTIFIC INVESTIGATOR

Senior Research Scientific Investigator with extensive experience in planning and conducting drug discovery research using current molecular and cell biology approaches. Result oriented with a strong background in identification of mechanism of action pathways, and their use in development of in vitro biomarkers, screening and profiling assays (reporter, proliferation, apoptosis, cytotoxicity, colony-forming assay, protein and gene expression, western, EIA, EMSA). A common-sense leader who recruits and mentors highly competent research associates and fosters excellence in all aspects of program execution. Additional technical expertise includes:

* Mammalian cell culture and transfection* Establishment of transformed stable cells* Receptor Degradation assay* siRNA knockdown* Real Time PCR* Gene cloning and site directed mutagenesis* Peptide phage library construction and screening* SPA, IEF

* Word, Excel, Prism, Deltagraph* cDNA library construction and screening* PCR arrays, Signal Transduction arrays, Phospho-protein arrays

PROFESSIONAL EXPERIENCECHIMEROS INC., San Diego, CA 2010Contract Scientist,* Established in vitro protocols for new cell lines* Screened for novel siRNA delivery systems

ANAPHORE INC., La Jolla, CA 2009Contract Scientist,* Constructed, panned and screened Phage Display libraries

* Developed competition ELISA for IL23

HOLLIS-EDEN PHARMACEUTICALS, San Diego, CA 2007 - 2009Senior Scientific Investigator, Oncology* Led investigation to determine the Mechanism Of Action of the lead clinical stage compound* Identified three cellular pathways involved in the activity of the lead compound while following the effect on specific biomarker, and determined the steps inthe pathways where the lead compound acted* Wrote experimental parts of IND

LIGAND PHARMACEUTICALS, San Diego, CA1994 - 2007

Senior Research Scientist, Molecular Oncology 2002 - 2007* Established proof of concept for new approach to prostate cancer targeting theandrogen receptor.* Developed degradation assay for Androgen-Independent Prostate Cancer (AIPC) identified as key assay for profiling small molecules.* Initiated research on prostate cancer using PPAR gamma as a target.* Initiated cancer research and assay development targeting the Hedgehog pathway.* Developed secondary assays to support medicinal chemistry's efforts for the AIPC and the Hedgehog projects.

8/6/2019 Scientist/Senior scientist/ Senior Scientific Investigator

2/3

Senior Research Scientist, Transcription Research 1997 - 2002Participated in the development and implementation of secondary assays used to characterize thrombopoietin (TPO) receptor agonists for the Ligand/GlaxoSmithKline partnership. Success in this partnership resulted in multiple milestone payments to Ligand. The drug is now in Phase III clinical trials. The drug continues to meet expectations. Promacta was awarded the 2009 Prix Galien USA September 30,2009.

EVELYNE ODETTE, Ph.D. Page Two

Senior Research Scientist, Molecular Biology 1994 - 1997* Established new reporter assays targeting inflammation. Several are still in use.* Developed in vitro assays for Ligand/Abbott inflammation collaboration.

AMGEN, Inc., Thousand Oaks, CA 1986 - 1994Research Scientist I, Inflammation Research 1992 - 1994* Constructed random peptide phage display library producing circular peptides.* Generated three peptide antagonists targeted against inflammation-associated chemokines and adhesion molecules. One peptide was produced using the peptide phage display approach, the other two using a rational approach.

Research Scientist, Molecular Genetics 1991 - 1992* Created erythropoietin (EPO) mimetics using random peptide-phage display technology.* Identified 17 candidates that were characterized with regard to biological activity by the EPO project team.

Research Associate III, Molecular Genetics 1986 - 1991* Generated second generation EPO analogs by introducing new N-Glycosylation sites to EPO using site-directed mutagenesis in conjunction with antibody mapping.One of these analogs is Aranesp, Amgen's second-generation Epogen* Created stable mammalian cell lines for each new variant.* Analyzed physical properties of the EPO analogs using partial carbohydrate digestion, Western analysis, and isoelectric focusing.

* Analyzed biological activity in colony forming assays using hematopoietic progenitor cells from bone marrow. One analog is twice as active as the native protein and is approved for use in Europe.* Expressed and purified silk-like protein, proteinase S, PDGF, PD-ECGF, NGF andBDNF in yeast to determine the feasibility of using yeast as a production system.

POST DOCTORAL EXPERIENCE

BOSTON MEDICAL SCHOOL/VA Hospital, Biochemistry, Boston, MA 1985 - 1986Research Biochemist (Dr. Barbara Smith)* Characterized a new short chain collagen protein.

DANA-FARBER CANCER INSTITUTE, Molecular Cancer Genetics, Boston, MA 1983 - 1985Post-Doctoral Fellow (Dr. Ruth Sager)* Studied genotypic environment in which ras and myc oncogenes were tumorigenic.Tumor formation in nude mice injected with CHO cells transfected with ras and myc required both Ras and Myc together.

BRANDEIS UNIVERSITY, Waltham, MAINSTITUTE FOR PHOTOBIOLOGY OF CELLS AND ORGANELLES 1982 - 1983Post-Doctoral Fellow (Dr. Jerome Schiff)* Optimized protein synthesis in isolated, physiologically viable, intact pure m

8/6/2019 Scientist/Senior scientist/ Senior Scientific Investigator

3/3

itochondria from a mutant of Euglena Gracilis.

EDUCATION

Ph.D., Plant Biology Department - Cornell University, Ithaca, NYDissertation title: Gibberellin A20 metabolism in seedlings of G2 peas.Advisor: Peter J. Davies

MS, Plant Biology - Cornell University

BS, Biology - New York University, New York, NY